Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.
about
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for preventionHIV, HCV, and Health-Related Harms Among Women Who Inject Drugs: Implications for Prevention and TreatmentHepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and preventionOutcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response.Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.Women, drugs and HIV.The Cascade of Care for an Australian Community-Based Hepatitis C Treatment ServiceEpidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol.Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study.Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.The impact of HIV treatment-related stigma on uptake of antiretroviral therapy.Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.The role of Aboriginal community attachment in promoting lifestyle changes after hepatitis C diagnosis.Direct-acting antiviral agents for HCV infection affecting people who inject drugs.Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment.Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals.High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001-2012: a multi-level modelling analysis.High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?Commentary on Gountas et al. (2017): Time to focus on empirical evidence for HCV treatment as prevention.Death from liver disease in a cohort of injecting opioid users in a Swedish city in relation to registration for opioid substitution therapy.Health workers' support for hepatitis C treatment uptake among clients with a history of injecting.Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference.Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.Recommendations for the management of hepatitis C virus infection among people who inject drugs.Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study.The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era.Hepatitis C virus prevalence and associated risk factors among Indigenous Australians who inject drugs.Global Mortality Burden of Cirrhosis and Liver Cancer Attributable to Injection Drug Use, 1990-2016: An Age-Period-Cohort and Spatial Autocorrelation Analysis.Care and treatment of hepatitis C among Aboriginal people in New South Wales, Australia: implications for the implementation of new treatments.Hepatitis C Treatment Outcomes for People Who Inject Drugs Treated in an Accessible Care Program Located at a Syringe Service Program.The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs.Integrated Models of Care for People Living with Hepatitis C Virus and a Substance Use Disorder: Protocol for a Systematic Review.From client to co-worker: a case study of the transition to peer work within a multi-disciplinary hepatitis c treatment team in Toronto, CanadaKnowledge of naloxone and take-home naloxone programs among a sample of people who inject drugs in Australia: Variations across capital cities
P2860
Q26801456-8EEF9F76-442B-43C5-BBCC-98284773588BQ26991563-23A39930-548D-4FB7-A35C-E7CFA47B15FAQ27014761-7B93F458-F8D6-4176-8A32-46E456E155C4Q33821728-6CA9C266-42D1-40A8-87E0-A6F3E04F35E9Q34028307-E9E5A738-91ED-4B45-B7C6-3E923D4CAB54Q35838614-C4DCB5B4-631D-4717-9245-8F0F7E4EDA0CQ35839915-9504A829-B6EB-477B-8818-D81DFFBC85EAQ35865346-EEB6121E-3D4F-434B-BA04-80E832B8ECDBQ36021369-8DFE3D0A-1EAC-4CD0-B1BD-704CF3F023DEQ36079786-9816A660-DBEA-4C13-8EB5-25FDA6A0672BQ36192804-D9ECCF2A-325E-4B62-B761-1361A072C338Q36425280-C7F2EA7B-2C1A-4069-92F6-C79FC1D13DF9Q36802839-0E36F76B-6D02-40C9-B763-0D0809AA2CEFQ37540678-B53C8A50-9783-4280-97A7-BACA295A7FBBQ38613271-7EDBFD76-9535-4437-8ACE-2DE2817CB34AQ38838703-637DA2E6-9E2C-48D2-ABFE-2E5635DD6C2DQ38873165-1365A365-7BAB-4E6F-A0CA-BC3C1B43BC57Q38907436-031513D7-BFF4-4352-957C-26D8E056C183Q39138754-540D17DC-8D54-4FC4-B84C-510CEA59B4CBQ40082158-023DA81E-1435-4C71-9F7D-30AA8CB5B269Q40092669-252904AF-F303-4EF4-971D-29D852AFFD97Q40170929-D420D387-FD21-4764-AD3A-C9BA922549B2Q40652912-F8F7DEDF-629E-4913-95A6-EB87E8F54DCAQ40789247-311FD102-6C3F-477A-8844-0965614DEE84Q40818421-BA02871F-6373-434A-A92E-165691A9868AQ40959924-34296CD5-7453-4E4F-9CBC-78791ED59D47Q41047662-71757D7B-61C4-4DC5-BC4E-DB28D54918D5Q41210837-6EBDE78F-3274-4C0B-B580-1A07870DD91DQ42955909-10A1A920-0439-4B9A-BC16-5E86F5AAF52EQ45324363-24F8B56E-CF62-4F0C-8528-0FB3189B21D1Q47800804-7FA8D74F-251C-4DF8-8AB5-03DDDA9C0893Q50960520-E761AC75-DB37-4B89-AFC5-CBAB593F0222Q52592715-88F3F1D0-FA7E-43C4-AD2E-959669CE29F3Q52631124-C5CB6003-A462-4629-8972-A02DBA7861F6Q54216905-F5931A86-6414-4803-BD30-AAD2E6E438D8Q58782699-F7F7F808-690F-4C28-9346-203C77F121D0Q59259851-6219634A-0760-44CE-A128-C1FAF1C2D4A1
P2860
Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Uptake of hepatitis C treatmen ...... grams in Australia, 1999-2011.
@en
Uptake of hepatitis C treatmen ...... grams in Australia, 1999-2011.
@nl
type
label
Uptake of hepatitis C treatmen ...... grams in Australia, 1999-2011.
@en
Uptake of hepatitis C treatmen ...... grams in Australia, 1999-2011.
@nl
prefLabel
Uptake of hepatitis C treatmen ...... grams in Australia, 1999-2011.
@en
Uptake of hepatitis C treatmen ...... grams in Australia, 1999-2011.
@nl
P2093
P2860
P356
P1476
Uptake of hepatitis C treatmen ...... ograms in Australia, 1999-2011
@en
P2093
P2860
P304
P356
10.1111/JVH.12129
P577
2013-07-01T00:00:00Z